■这项工作报告了持续时间,安全,和玻璃体内浆液曲安奈德(TA;1.0mL40mg/mLTA离心机浓缩成0.1mL颗粒)的活力,以治疗囊样黄斑水肿(CME)。
■回顾,对接受玻璃体内浆液TA注射的患者进行了连续审查,2009年7月至2018年12月。
■在120名患者的143只眼睛中,浆液TA解析CME平均327.15(SD=213.11)天,或10.76(SD=7.00)个月,每次玻璃体内注射(n=466)。在需要多次注射的100只眼睛中(n=423),平均持续时间为270.95(SD=177.14)天,或8.91(SD=5.82)个月,在注射之间。在43只单次注射的眼睛中,持续时间为749.30(SD=483.17)天,或24.63(SD=15.88)个月。平均持续时间从337.89(SD=210.46)天减少,或11.11(SD=6.92)个月,在非玻璃体切除术至279.74(SD179.63)天,或9.20(SD=5.91)个月,在玻璃体切除的眼中(n=74次注射,t=2.24,P=0.014,1尾)。光学相干层析成像显示的中央中央凹厚度减少了173.89μ(SD=147.56μ),从459.16μ(SD=47.14μ)到285.27μ(SD=77.27μ;t=-25.31,P<.001),43.41天内(SD=36.86)。视力从20/100(logMAR0.70,SD=0.33)提高到20/74(logMAR0.57,SD=0.31;SD=0.21;t=-11.01,P<.001),33.98(SD24.98)天内。31只眼睛中有15只(48.39%)进行了白内障摘除术。57只眼睛(39.86%)出现了类固醇反应(从基线增加>10mmHg)94.79天(SD=85.52天),或3.11(SD=2.81)个月,注射后。
■单次注射浆液TA平均持续10.76个月,CME和视敏度显着提高。不良的眼部影响与目前可用的相当,长期的,可植入类固醇。浆液TA似乎是一种容易重现的,安全,和具有成本效益的替代长期眼内类固醇递送。
UNASSIGNED: This work reports the duration, safety, and viability of intravitreal slurry triamcinolone acetonide (TA; 1.0 mL of 40-mg/mL TA centrifuge concentrated into a 0.1-mL pellet) to treat cystoid macular edema (CME).
UNASSIGNED: A retrospective, consecutive review was conducted of patients undergoing intravitreal slurry TA injections, July 2009 to December 2018.
UNASSIGNED: In 143 eyes of 120 patients, slurry TA resolved CME for a mean of 327.15 (SD = 213.11) days, or 10.76 (SD = 7.00) months, per intravitreal injection (n = 466). In 100 eyes requiring multiple injections (n = 423), mean duration was 270.95 (SD = 177.14) days, or 8.91 (SD = 5.82) months, between injections. In 43 single-injection eyes, duration was 749.30 (SD = 483.17) days, or 24.63 (SD = 15.88) months. Mean duration decreased from 337.89 (SD = 210.46) days, or 11.11 (SD = 6.92) months, in nonvitrectomized eyes to 279.74 (SD 179.63) days, or 9.20 (SD = 5.91) months, in vitrectomized eyes (n = 74 injections, t = 2.24, P = .014, 1-tailed). Central foveal thickness as shown on optical coherence tomography decreased by 173.89μ (SD = 147.56μ), from 459.16μ (SD = 47.14μ) to 285.27μ (SD = 77.27μ; t = -25.31, P < .001), within 43.41 days (SD = 36.86). Visual acuity improved from 20/100 (logMAR 0.70, SD = 0.33) to 20/74 (logMAR 0.57, SD = 0.31; SD = 0.21; t = -11.01, P < .001), within 33.98 (SD 24.98) days. Fifteen of 31 phakic eyes (48.39%) underwent cataract extraction. Fifty-seven eyes (39.86%) developed a steroid response (> 10 mm Hg increase from baseline) 94.79 days (SD = 85.52 days), or 3.11 (SD = 2.81) months, following injection.
UNASSIGNED: A single injection of slurry TA lasted on average 10.76 months with significant improvement of CME and visual acuity. Adverse ocular effects were comparable to currently available, long-term, implantable steroids. Slurry TA appears to be an easily reproducible, safe, and cost-effective alternative to long-term intraocular steroid delivery.